We employed Glyco-polypeptides in human subjects to induce leucocyte immune production which including interleukins and Tumor Necrotizing Factors (TNF) result in necrosis, fibrinolysis, anti-metastatic effects in late-stage carcinoma of lung, prostate, and bladder, and achieved excellent anti-tumor effects.

Then investigation were carried out in animal. The cancer cells cultures were performed in our laboratory. By injection of cancer cell fluid into peritoneal cavity of animal in 6 groups (white rabbits). Tumor growth in animals were obtained in 3 months, then polypeptides were injected into peritoneal cavity every 2 weeks at a dose of 15mg for 6 months, then animals were sacrificed and examined shown no tumor growth in the peritoneum. We applied FDA phase 2 clinical trials with IND 116911. Tests were carried out in 2 groups, the low dose group on 10 mg/kg/day, and high dose group on 50 mg/kg/day for a period of more than 6-8 months. A total number of 35 patients with 3rd and 4th stage of refractory solid tumors of lung, prostate, and bladder were enrolled from referring center, 24 patients were not eligible and excluded, whom at least previously failed on two regimens of chemotherapy and /or failed on radiation therapy, the rates of complete response and partial responses in high dose cohort were astonishing with rate of 74 % and 20 % respectively. Stable diseases and Progressive diseases in high dose cohort were astonishing with rate of 0% and 5.7%. The implications and results of the findings are discussed. P value ≤0.05 Our findings in this study were correspondence with Dr. Maurer, Dr. Eckert, Dr. Harrach (5, 9,11,12, 21, 31, 41) and many other authors. Glyco-polypeptides in treating various type of cancers only high dose are effective. There were no hematological, hepato-renal toxicities.

Liao BS, Harvowitz E, Liao A, Liao A, Liao B, et al. (2021) Glyco-polypeptides (Comosain) and chimeric white blood cell therapy in late-stage refractory solid carcinoma of lung, prostatic and bladder cancers review of 35 cases J Hematol Transfus 8(3): 1099.

Administered of oral Glyco-polypeptides (Comosain) in cancer treatment in nonclinical trials has been reported as early in 1968 by Wolf M, & Ransberger k (1), In vitro and animal studies have suggested of anti-metastatic effect for Glyco-polypeptides (Comosain). Batkin & Taussig (2,3) in 1988 reported that orally administered Glyco-polypeptides (Comosain) reduced the incidence of pulmonary metastasis in Lewis lung cancer cells in mice. In recent years, 1988 Batkin & Taussig (4) suggested the antitumor mechanisms are due to fibrinolytic effect in Glyco-polypeptides (Comosain). Taussig & Batkin in 1988 (5) discovered that Glyco-polypeptides (Comosain) has antiPlatelet aggregation effects. Taussig and Batkin in 1985 (5) also discovered Inhibition the growth of tumor cells such as Lewis lung carcinoma, V-8 lymphoma, MC1-1 acites, KATO-gastric carcinoma cells. Maurer & Hozumi, in 1994 (6) Discovered Glycopolypeptides (Comosain) Induced Differentiation in leukemic cells. Hale, & Haynes in 1992 (7) and Cantrell et. in 1996 had suggested that due to Major Histocompatibility Protein Kinases, such as MMAPK (Major Mitogen Activating Protein Kinase) and TPK (Tyrosine Phosphorylation Kinase) inhibitors were activated by Glyco-polypeptides (Comosain). T-cell activation and cascade production of Interleukin 2, 6, 8, and TNF-a (Tumor Necrotizing Factors) via CD-2, CD-3 surface antigen of WBC.

Garbin, Harrach, Eckert, & Maurer in 1994 (15) and Hale, & Haynes in1992 (7) also suggested that Glyco-polypeptides (Comosain) will reduce surface antigens of CD-44, CD-44v, CD44s, CD45, & CD 47 in tumor cells of breast carcinom.

From the experimental studies above, we conclude that activation of Glyco-polypeptides (Comosain) in lymphocytes and T-cells have anti-metastatic effects both in vitro and in vivo.

In the present study, we compared the modulation of low dose cohort and high dose cohort of Comosain administration to the patients with stage 3, and stage 4, refractory solid tumors, which including various types of carcinoma of lung, prostate and bladder. All patients failed previously on at least two regimens of chemotherapy and /or failed on radiation therapy, The treatment were carried out for at least 24 to 28 weeks, the complete blood count, liver, renal function, hematopoietic elements, tumor markers were evaluated at an interval of every 2 to 4 weeks, the computerized tomography scan were performed at an interval of every 3 to 4 months. The size of tumors were measured, the tumor markers were recorded for the evaluation of complete response (CR), partial response, (PR), stable disease (SD), and progressive disease (PD) according to the Standard Response Criteria of National Cancer Institute (NCI). The Common toxicity were recorded by using NCI’s Standard Toxicity Criteria. The results of CR and PR were promising and astonishing when Comosain were administered in patients of high dose group.

Glyco-polypeptides (Comosain) were purchased from Natural Organics Laboratories, Amityville, N.Y., Capsules to contain Glycopolypeptides (Comosain) were purchased from Capusugel Co. Greenwood, North Carolina. Comosain were analysed by using SDS-Polyacryl-Amide Gel Electrophoresis (SDS-PAGE), Cation Exchange Chromatography (CEC), Florescence High Performance Liquid Chromatography (FPLC) to determinate the purity and separation of Glyco-polypeptides (Comosain) fraction of F1, F2, F3, F4, F5, F6, F9 in stem. Glyco-polypeptides (Comosain) (Harrach et al 1994 (9)) were detected by Amperometric detection. Monosaccharides fraction are L-fructose, D-galactosamine, D-glucosamine, D-xylose, D-mannose, D-glucose, D-galactose, D-fructose, and Deoxyribose [Figure1].

Figure 1 Lung cancer pre and post treatments:.

Clinical Application and Study protocol;

1. Patients Eligibility and Selection (Total number of patients: 35)

(I) Patients with stage III and IV solid cancer of lung, prostate and bladder with tissue proof of well-documented malignancies, whether by tissue biopsies and have not been helped by conventional radiation therapy and/or chemotherapies for at least two separated regimens are eligible for this study.

(II) Or patients must have no available therapy known to provide clinical benefit. For example, the lung, prostate and bladder cancer patients must have failed at least 2 chemotherapy regiments in the metastatic setting.

(III) Additionally

Patient’s age is between 18 and 95+ years, not taking anticoagulants, have no history of abdominal fistula, gastro enteral perforation, peptic ulcer diseases, or intra-abdominal abscess within 4 months prior to study enrollment, and patient has not had major surgery within 4 weeks prior to study enrollment, and other requirements are same as NCI’s criteria. Also, Patient does not have uncontrolled hypertension, diabetes, or cardiac arrhythmia, and not allergic to Glyco-polypeptides (Comosain)-containing products, not pregnant or breastfeeding. Patient’s WBC count ≥ 3k/uL, hemoglobin ≥ 9.0 g/dL, platelet counts must be ≥ 100,000/uL, and INR < 1.5 have no significant abnormal hepatic and/or renal function [Figure 2-4].

Figure 2 Lung cancer pre and post treatments:

Figure 3 Lung cancer pre and post treatments:

Figure 4 Prostate cancer pre and post treatments:

Patient’s tumors are measurable between 0.2 – 10+ cm in size and number between 1–15+. All measurable tumors that have spread to the bones, liver, lung, kidney, and abdomen will be included in the data analysis.

Patients who are eligible for this study will be randomly assigned to either the low dose cohort or the high dose cohort by a coin toss. Each study subject will be assigned a patient number for the purpose of this study.

Methods of Study

The Dose of Comosain at 50 mg /kg/day is extrapolated from in vivo animal studies and determined to be safe by a Safety study on healthy human subjects.

The High Dose cohort will be given Comosain at 50 mg /kg/ day (at a body weight of 50- 60 kg) to a maximum of 2400 mg / day and divided into 2 doses/day of 1200 mg/dose, and taken with meals. Low dose Cohort patients will be given Comosain at 10mg/kg/day, that is 500 mg /day, divided into two doses of 250 mg /dose and taken with meals [Figure 5-7].

Figure 5 Prostate cancer pre and post treatments.

Figure 6 Prostate cancer pre and post treatments.

High Dose Cohort – The number of patients will be at least 21.

Low dose Cohort--The number of patients will be at least 14.

(A). Blood/laboratory tests will be scheduling every 2-4 weeks, which include CBC, Chemistry-7, Chemistry-24, liver and renal function, CEA, CA125, CA153, CA199, PSA,TSH, alfa-FetoProtein and other tumor markers.

(B). Radiological tests will be assessed every 3-4 months. Each patient will be also assessed every 4 weeks for any side effects that they may have experienced.

(C). Using NCI standard toxicity criteria for hematology, renal, and hepatic system evaluation.

(D) Adverse events, serious adverse events reporting information also using NCI criteria

Duration and Route of Administration

The patients will be evaluated by blood tests and/or CT scans at the end of each 6 weeks cycle and at six months for signs of disease progression. If the disease did not progress, then treatment will continue, and the patient will be evaluated every six months thereafter until the investigator determines otherwise. If the disease did progress, then the patient will be taken off the study. On the Humanitarian base, the low dose group patients will be transferred to the high dose group due to lack of efficacy in the treatment [Figure 8-10].

Figure 8 Breast cancer pre and post treatment (Liver Mets, 9.2cm shrinkage to 2.6cm).

Figure 9 Ovarian cancer pre and post treatment.

Ovarian Cancer 4th

Figure 10 Ovarian cancer pre and post treatment

Ovarian Cancer 4th.

Results 1

At the end of six months, each patient will be determined whether or not to continue with this therapy and assess the efficacy of the therapy by using NCI Standard response Criteria:

I). Evaluation of Target Lesions

(A) Complete Response (C R): Disappearance of all Target lesions, and lymph nodes must be reduced < 10mm.

(B) Partial Response (P R): At least a 30 % decrease in the sum of the diameters of target lesions compared with the baseline sum diameters.

(C) Progressive Disease (P D): At least a 20% increase in the sum of the diameters of target lesions compared with the smallest sum on study. In addition, the sum must demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progressions.

(D) Stable Disease (S D): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference to the smallest sum diameters while on study.

II). Evaluation of Non-Target Lesions

(A) Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be < 10mm short axis.

(B) Non-CR/ Non-PD: Persistence of one or more non-target lesion(s) and /or maintenance of tumor marker level above the normal limits.

(C). Progressive Disease (PD): Appearance of one or more new lesions and/ or unequivocal progression of existing non target lesions. Unequivocal progression should not normally trump target lesion status.

Results 2

Age distribution, all the patients are mainly in their 6 decade and above. The disease classification and distribution are as following: lung carcinoma account for 45.7% (16/35), in prostate carcinoma the incidence is 42.8% (15/35), in bladder carcinoma the incidence are 11.4% (4/35).

The overall clinical response rate in high dose group patient:

Lung CA

Prostate CA

The tumor markers such as CEA,CA-125, CA-199, PSA, and alpha-feto-protein are been monitored, their values are corresponding to the tumor masses, they return to normal value when tumor have CR, and when the tumor progress the tumor marker value are elevated.

The serious adverse effect in toxicity in both groups are not observed, there were no serious hematopoietic or hepato renal toxicity, no anaphylactic reaction or life threaten events. There were rarely minor side effects such as nausea, vomiting, diarrhea, palpitation, headache, insomnia, pruritus, urticaria, and skin rash. We conclude that Glyco-polypeptides (Comosain, Ananases) administered in an amount of 2500 to 3000 mg/day to the patients with average body weight are effective and non toxic.

In summary, Glyco-polypeptides (Comosain) administration in double-blind study showed effectiveness only in patients with high dose cohort of 50 mg/kg/day regimen. The low dose cohort showed no efficacy at all. Both groups did not show serious adverse effects such as leukopenia, anemia, hepato-renal toxicity, anaphylactic reaction, and life-threaten events. Minor adverse effects such as nausea, vomiting, diarrhea, urticaria, insomnia, palpitation, pruritus, and headache occurred rarely.

The remarkable cancercidal effects probably due to massive production of Interleukin-II, VI, VIII, and tumor necrotizing factors from CD-2, CD-3 in monocytes and lymphocytes. The fibrinolytic effects on tumor surface antigens of CD-44, CD-44V, CD-44S, CD45, and CD-47 which induce dehydration, necrosis, and possible calcification in the tumor cells. This action mechanism of Glycopolypeptides (Comosain) is mainly attributed to inhibition of 2 kinases: Major Mitogen Activating Protein Kinases and Tyrosine Phosphorylation Kinases. In the WBC culture test with concentration of Glyco-polypeptides (Comosain) in an amount of 1 mg/ml will increase the production of Interleukin II by 400 times/106 WBC, Interleukin-6 by 650 time/106 WBC, and the TNF by 42 times/106 WBC.

The results in the high dose group patients showed remarkable CR rates of 74%, PR rate of 20%, SD rate of 0%, PD rate of 5.7%. Dr. HR Maurer in his complimentary tumor therapy also showed Glyco-polypeptides (Comosain) in an amount of 1000-to-3000 mg/day for the period of 1 to 3 years has no severe side effects nor any life threaten events.

1. An acidic Bromelain Proteinase; J Protein Chem. 1998; 17: 351-361.

2. Barnes S. Effect of genistein on in vitro and in vivo models of cancer: J Nutr. 1995; 125: 777S-783S.

3. Guthrie N and Moffatt M. Inhibition of proliferation of Human breast cancer cells by naringenin, a flavonoid in grapefruit: National Forum Breast Cancer. 1993; 119.

4. Batkin S, Taussig SJ, Szekerezes J. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity, J. Cancer Res. Clin. Oncol.1988; 114: 507-508.

5. Birch M, Miychell S. and Hart IR, Isolation and characterization of human melanoma cell variants expressing high and low levels of CD 44. Cancer Res. 1991; 51: 6660-6667.

6. Cantrell. Micosomal study of Bromelain and its intracellular signal transduction namely, T-cell receptor ( TCR ) /CD3 signaling and Interleukin II ( IL-2 ) production, which are activated by Major Histocompatibility Complex ( MHC ) expressed on antigen presenting cells (APC ). Annu Rev Immunol. 1996; 14; 259-274.

7. Castillo MH and Perkins E J H Campbell, R Doerr, J M Hassett. et al. The effect of Bio-flavonoid-Quercetin on squamous cell carcinoma of head and neck origin, Am J Surg. 1989; 158: 351-355.

8. Cooreman W. Bromelain Pharmacological Enzymes-Propoerties and assay method. 1978; 07-12. Story-Scientia Scientific Publishing Co.

9. Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80, Lymphocyte homing receptor molecule augment human peripheral blood T-cell activation. J Immunol. 1990; 144: 7-15.

10. Desser L, Rehberger A, Paukovits, W. Proteolytic enzymes and amylase inducecytokine production in human peripheral blood mononuclear cells in vitro, Cancer Biother. 1993; 9: 253-263.

11. Desser L, Rehberger A, Kokron, E, Paukovits, W.Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparation, Oncology. 1993; 50: pp. 403-407.

12. Eckert, K, Grunberg E, Garbin F, Maurer HR. Preclinical studies with prothymosin a-1 on mononuclear cells from tumor patients, Int J Immunopharmacol. 1997; 19: 493-500.

13. Eckert K, Grabowska E, Strange R, Schneider U, Maurer HR, et al. Effects of oral bromelain administration on the impaired immunocytoxicity of mononuclear cells from mammary tumor patients. OncoloRep. 1999; 6: 1191-1199.

14. Felicia VS. Najla, Chambers AF, Moussa M, CarrollG KK. Inhibition of breast cancer cell proliferation and delay of mammary tumor-genesis by flavonoids and citrus juices. Nutr Cancer. 119; 26: 167-181.

15. Filipova Y. In L-pyroglutamyl-L-Phenyl-Alanayl-L-Leucin-PNitroaniline, A chromogenic substrate for thio-proteinase assay.; Anal Biochem. 1984; 143: 293-297.

16. Gallatin WM, Wayner EA, Hoffman P, John T St, Butcher EC. Structure homology between lymphocyte receptor for high endothelium and class III extracellular matrix. Proc National Acad Sct USA. 1989; 86: 4654-4658.

17. Garbin F, Harrach T, Eckert K, Maurer HR. Bromelain proteinase F9 augments human lymphocyte- mediated growth inhibition of various tumor cells in vitro. Int J Onco. 1994; 5: 197-203.

18. Garbin F, Harrach T, Klaus E, Maurer HR, Büttner P. Prothymosin a-1 augments deficient antitumor activity of monocyte from melanoma patients in vitro; Anticancer Res. 1994; 14: 2405-2412.

19. Grabowska E, Eckert K, Fichiner I, Schultze-Forster,K, Maurer HR. Bromelain proteases suppress growth, invasion and lung metastasis of B16F10 mouse melanoma cells .Int J Oncol. 1997; 11: 243-248.

20. Gunthert U, Hofman M, RUDY w, Reber S, Zöller M, et al. A new variant of glycoprotein CD44 Confers metastatic potential to rat carcinoma cells. Cell. 1991; 65: 13-24.

21. Harrach T, Gebauer F, Eckert K, Kunze R, Maurer HR. Bromelain proteinases modulate the CD44 expression on human Molt 4/8 leukemia and SK-Mel28 melanoma cells in vitro. Int J Oncol. 1994; 5: 485-488.

22. Harrach T, Eckert K, Schulze-Forster K, Nuck R, Grunow D, et al. Isolation and partial characterization of basic proteinases from stem bromelain: J Protein Chem. 1995; 14: 41-52.

23. Harrach T, Eckert K, Schulze-Forster K, Nuck R, Grunow D, et al. Isolation and characterization of two forms of an acidic bromelain stem proteinase. J Protein Chem. 1997; 20: 53-64.

24. Harrach T, Eckert K, Schulze-Forster K, Nuck R, Grunow D, et al. Isolation and partial characterization of basic proteinases from stem bromelain. J Protein Chem. 1998; 17: 351-361.

25. Haynes BF, Telen MJ, Hale LP, Denninget SM. CD 44 : a molecule involved in leucocyte adherence and T-cell activation. Immunol Today. 1989; 10: 423-428.

26. Heinckie RM, van der Wal L, Yokoyama M. Effect of bromelain (ananase) on human platelet aggregation, Experientia. 1971; 28: 844- 845.

27. Hofman M, Rudy W, Gunthert U. A link between ras and metastatic behavior of tumor cells: ras induces CD44 pomoter activity and leads to low level expression of metastatic specific variants of CD44 in CREF cells. Cancer Res. 1993; 53: 1516-1521.

28. Huet S , Groux H, Caillou B, Valenton H, Prieur AM, et al. CD44 contributes to T cell activation. J Immunol. 1989; 43: 789-801.

29. Ishihara H, Takahashi N, Oguri S, Tejima S. Complete structure of the carbohydrate moiety of stem bromelain, Biol Chem. 1979; 254; 10715-10719.

30. Kandaswami C, Perkins Eet, Soloniuk DS, Drzewiecki G, Middleton Jr E. Anti-proliferative effects of citrus flavonoids on human squamous cell carcinoma in vitro. Cancer Lett. 1991; 56: 147-152.

31. Kleef R, Delohery TM, Bovbjerg, DH. Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease-5. Pathobiology. 1996; 64: 339-346.

32. Lee K, Albee K, Bernasconi RJ, Edmundset T. Complete amino acid sequence of ananain and comparison with bromelain and other plant cysteine proteinases. Biochem J. 1997; 327: 199-202.

33. Liao B. Reported plant extracts derived from anans Comosus as anti cancer agents in animal experiments in breast and colonic carcinomas. Internal communication, non-publication materials. 1984.

34. Liao B, Liao A, Liao A, Liao J. Bioflavonoids derived from Fructus Crateagus served as anti-cancer and anti-lipidemic agents. 2003.

35. Livio and De Gaetano. Bromelain and its platelet aggregation effect. Drug Exp Clin Research. 1978; 1: 49-53.

36. M1C2, CD6, CD7 and Leu 8/Lam1 surfaces molecules and markedly enhances CD2-mediated T cell activation. J Immunol. 1992; 149: 3809-3816.

37. Manach C. Bioavailability, metabolism, and physiological impact of 4-oxo-flavonoids: Nutrition Reseach. 1996; 16: 517-544.

38. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco, L. The origin and function of tumor associated macrophages. Immunology Today. 1992; 13: 265-270.

39. Matsumoto G, Ghiem MP, Nozaki N, Schmits R, Penninger JM. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-Activated killer cell cytotoxicity, J Immunol.1998; 160: 5781-5589.

40. Maurer H, Eckert K, Szekerezes J. Bromelain in the complementary tumor therapy. Journal of Oncology. 1989; 31: 66-73.

41. Maurer HR, Hozumi M, Honma Y, Okabe-Kado J.; Bromelain. induces the differentiation of leukemic cells in vitro : An explanation for its cytostatic effect? Planta Med. 1988; 54:377-381.

42. Metzig C & Eckert, K. Bromelain prevents adhesion of platelet to endothelial cells of blood vessel; In. Vivo. 1999; 13: 7-12.

43. Morita A & Uchida D. Inhibition of platelet aggregation in vitro with bromelain Treatment; Arch. Int. Pharmacodyn. 1979; 239: 340-350.

44. Mynott A & Engwerda C. T-cell receptor ( TCR.)/ CD3 , CD2 activated by bromelain through the Mitogen Activated Protein (MAP) Kinase Pathway. US patent7. 2010; 833: 963.

45. Napper and Bennet. Further purification and characterization of multiple forms of Bromelainases derived cysteine proteinases Ananain and Comosain. Biochemico. Journal. 1994; 301: 727-735.

46. Netti C, & Bandi, G. Bromelain and its pharmacological effect on edema. Pharmaco. 1972; 27: 453-466.

47. Ota S, Muta E, Katahira Yand OkamotoY. Reinvestigation of fractionation and some properties of the proteolytically active components of stem and fruit bromelain, Journal of Biochemistry. 1985; 98: 219-228.

48. Peterson G & Barnes S. Genistein Inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and multidrug resistance gene: Biochem Biophys Res Commun. 1991; 179: 661-667.

49. Picker IJ , J de los Toyos, M J Telen, B F Haynes. In the Monoclonal antibodies (Lnt-Lu related p-80 ) and Pgp-1 antigens recognize the Hermes class of lymphocyte homing receptors. Journal of Immunology. 1989; 142: 2046.

50. Pirotta. Prolong the prothrombin and partial thromboplastin time in relative high doses of bromelain administration, Drug Exp. Clin. Research. 1978; 4: 1-20.

51. Ranelletti FO & Ricci R. Growth Inhibitory effect of quercetin and presence of Type-II estrogen-binding sites in human colon cancer cell lines and primary colorectal tumors; Int J Cancer. 1992; 50: 486-492.

52. Renzini. Bromelain increases permeability of antibiotic drugs; Drug Reaserch. 1972; 2: 410-412.

53. Revilla E & Ryan JM. Analysis of several phenolic compounds with potential antioxidant properties in grape extracts and wines by high performance liquid chromatography-photodiode array detection without sample preparation. J Chromatogr A. 2000; 881: 461-469.

54. Rollwagen. Induces the secretion of Interlukin IB, II-6, II-8, and tumor necrotizing factor (TNF ) : Immunology. 1996; 17: 548-550.

55. Rowan AD, Buttle DJ, Barrett A J. Ananain. A novel cysteine proteinase found in pineapple stem: Arch. Biochemistry Biophysics. 1988; 267: 262-270.

56. Rowan AD, Buttle DJ, Barrett AJ. The cysteine proteinases of the pineapple plant, Biochem J. 1990; 266: 869-875.

57. Rowan A. Pineapple cysteine endopeptidases, Methodology Enzymol. 1994; 244: 555-568.

58. Saija A & Scalese M. Plant and /or fruit flavornoids such as Rutin, Quercetin, Naringenin and Hesperetin in inhibiting tumor growth (Free Radical Biology and Medicine. 1995; 19: 481-486.

59. Scambia G & Ranelletti FO. Quercetin inhibits the growth of multidrug resistant estrogen receptor-negative MCF-7 human breast cancer cell line expressing type II estrogen-bnding sites: Cancer Chemotherapy, Pharmacology. 1991; 28: 255-258.

60. Scambia G & Ranelletti FO. Type II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids: International Journal of Cancer. 1990; 46: 1112-1116.

61. Seltzer A. Bromelain reduces blood level of prostaglandine E-2, and thromboxane-A-2 in exudates during acute inflammation.: EENT. Monthly: 1964; 43:54-57.

62. Singhal RL & Yeh YA. Qucercetin down-regulates signal transduction in human breast cancer cells: Biochemistry, Biophysics Research Commun. 1995; 208: 425-431.

63. Smyth R & Brennan R. Plasmin activation and its relation with bromelain. Arch Int. Pharmacodyn. 1962; 136: 230-236.

64. Taussig SJ, Batkin S, Szekerezes J. Inhibition of tumor growth in vitro by bromelain, an extract of the pineapple plant (ananas comosus ), Planta Med. 1985; 6: 538-539.

65. Taussig SJ, Batkin S, Szekerezes J. Bromelain: the enzyme complex of pineapple ( Ananas comosus ) and its clinical application. An update, J Ethnopharmacol. 1988; 22: 191-203.

66. Taussig SJ, Batkin S, Szekerezes J. Antimetastatic effect of Bromelain With or without its proteolytic and anticoagulant activity. J Cancer Res Clin Oncol. 1988; 114: 507-508.

67. Taussig SJ & Batkin S. Bromelain, the enzyme complex of Ananas Comosus. J Ethnopharmacol. 1988; 22: 191-203.

68. Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumor growth in vitro by Bromelain, an extract of pineapple plant ( ananas comosus). Planta Med. 1985; 6: 538-539.

69. Tinozzi & Venegoni. Bromelain in the tissue permeability of antibiotic drug; Drug Exp. Clinical Research. 1978; 1: 39-44.

70. Uhlig & Seifert. Bromelain and blood level of fibrinogen , and its fibrinolytic effects. Fortschritte Der Medizin. 1981; 15: 554-556.

71. Van de Winkel JGJ & Van Ommen R. Proteolysis induces increased binding affinity of the moncyte type II FcR for human IgG. J. 1989; 143: 571-578.

72. Verma AK & Johnson JA. Inhibition 7,12-Dimethylbenza-anthracene and N-Nitrosomethylurea induced of mammary cancer by dietary flavonoid Quercetin: Cancer Res. 1988; 48: 5754-5758.

73. Yasuda Y, Takahashi N, Murachi T. The composition and structure of carbohydrate moiety of stem Bromelain, Biochemistry. 1970; 9: 25- 32.

74. Yoshioka S, Izutsa K, Takeda Y. Inactivation kinetic enzyme pharmaceuticalsin aqueous solution. Pharm Res. 1991; 4: 480-485.

75. Zhao J & Wang J. Anti-tumor promoting activity of a polyphenolic fraction isolated from grape seeds and identification of procyanidinB5-3-gallate as the most effective anti-oxidant constituent. Carcinogenesis. 1999; 20: 1737- 1745.